Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:12/3/2009

WALTHAM, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on January 15, 2010 to holders of record of Series B stock at the close of business on January 4, 2010.

Such payment will cover the amount of all dividends accrued from October 1, 2009 through December 31, 2009.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Inverness Medical Innovations, Inc.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
2. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
3. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
4. Inverness Medical Innovations Announces Third Quarter 2008 Results
5. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
6. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
7. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
8. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
9. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
10. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
11. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):